MatchMedi
한국어

Patient pathway

New melanoma diagnosis

A first pathway for organizing pathology, staging, and handoff questions.

What this situation means

  • The first job is to understand the diagnosis, stage workup, and which specialist owns each next step.

What not to assume

  • Do not assume surgery, systemic therapy, or surveillance decisions are final before pathology and staging are clarified.

Information to gather

  • Pathology report
  • biopsy site and date
  • stage workup plan
  • surgeon and oncologist contact points

Bring to the surgeon

  • What margin is planned?
  • Is sentinel lymph node biopsy relevant?
  • What pathology result changes the plan?

Bring to the oncologist

  • Should medical oncology be involved now?
  • Will mutation testing be ordered?
  • What stage information is missing?

Bring to the trial team

  • Should trial search happen before first systemic therapy?

Related database records

source-backed record

Nivolumab

Used in care guidelines

Related treatment pages

immunotherapy

Immune checkpoint inhibitors

Immunotherapy can help the immune system recognize and attack melanoma, but it can also cause immune-related side effects.

immunotherapy

Immune checkpoint inhibitors

Immunotherapy can help the immune system recognize and attack melanoma, but it can also cause immune-related side effects.

targeted-therapy

BRAF + MEK combinations

These combinations target the MAPK pathway in BRAF V600 melanoma. They are grouped here so families can separate BRAF-targeted therapy from NRAS MEK-inhibitor research.

Related trial leads

A trial record is a lead only. The trial team must confirm whether it fits.

Phase 1/2 · unknown

NCT04375527

Supports the broader research concept of MEK inhibitor plus PD-1 inhibitor in melanoma, but not tunlametinib specifically.

Do not use this as evidence for tunlametinib plus nivolumab.

Phase 1 · unknown

NCT04835805

A sourced NRAS melanoma trial lead after anti-PD-1/PD-L1 therapy that may explain a remembered MEK/RAF plus PD-1 trial concept.

This is belvarafenib/cobimetinib/nivolumab, not tunlametinib/nivolumab.

Sources with the medical details

  1. Melanoma Treatment (PDQ) - Patient Version. Accessed 2026-05-20.
  2. 국가암정보센터: 면역관문억제제. Accessed 2026-05-20.
  3. PMDA review report: nivolumab. Accessed 2026-05-20.
  4. Drugs Approved for Melanoma. Accessed 2026-05-20.
  5. NCI: Drugs Approved for Melanoma, including encorafenib and binimetinib. Accessed 2026-05-20.
  6. NCI: Dabrafenib-Trametinib Combination Approved for Melanoma and Thyroid Cancer. Accessed 2026-05-20.
  7. Melanoma Treatment (PDQ) - Health Professional Version. Accessed 2026-05-20.